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Background: Balloon valvuloplasty (BV) is the primary therapy for congenital aortic valve stenosis (AS). Many reports describe short and 
intermediate outcomes, yet few describe predictors for long-term success. 
Methods: We performed a retrospective review of patients who underwent BV for congenital AS at our institution over the past 20 years. The 
following endpoints were evaluated: moderate to severe aortic insufficiency by echocardiography (AI), aortic valve replacement (AVR), repeat BV, 
surgical aortic valvotomy, and transplant/death. Regression analysis was performed to identify risk factors for all endpoints. 
Results: Between 1985 and 2009, 196 patients undergoing BV between the ages of 1 day to 30 years were followed for 4.45 (±4.85) years. 
Transplant or death occurred in 10 (5%) patients. Neonates were at greater risk for death or transplant (p<0.01). AVR occurred in 31 (16%) patients 
at a mean of 3.7 (±3.6) years. Lower baseline left ventricular shortening fraction (LVSF) (p<0.01) and younger patient age (p<0.01) were associated 
with AVR. AI occurred in 61 (32%) patients at a mean follow-up of 3.4 (±4.3) years. Balloon: annulus ratio >1 (p=0.02), lower LVSF (p<0.01), 
and a younger age at the time of BV (p<0.01) were associated with AI. Repeat intervention for recurrent stenosis (BV and/or surgical valvotomy) 
occurred in 25 (12.8%) patients at a mean of 3.7 (±5.4) years. Factors found to increase the rate of reintervention included: higher final valve 
gradient (p=0.04), lower LVSF (p=0.04), and additional left sided obstruction (p<0.01). At a follow up of 15 years post-BV, 54 (28%) patients had 
experienced an adverse event (repeat intervention, AVR, death or transplant). At a follow up of 10 years, 46 (23%) patients experienced an adverse 
event. Neonatal AS (p=0.04), lower LVSF (p<0.01) and higher final valve gradient (p<0.01) were associated with adverse events. 
Conclusions: BV confers long-term benefit to most patients with congenital AS. While 25% of patients required additional procedures (repeat BV, 
surgical aortic valvotomy or AVR) 77% were event free at 10 years. Neonates and patients with lower LVSF experienced worse outcomes.
